PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Clinical trials for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT explained in plain language.
Never miss a new study
Get alerted when new PROSTATIC NEOPLASMS, CASTRATION-RESISTANT trials appear
Sign up with your email to follow new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough prostate cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MK-5684 (opevesostat), alone or with other treatments, in people whose prostate cancer has spread and stopped responding to standard hormone therapy. The goal is to find safe doses and see if the drug can shrink tumors or lower PSA lev…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New drug combo aims to stall Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether adding pasritamig (a drug that helps immune cells attack cancer) to standard chemotherapy (docetaxel) can delay cancer growth in men with metastatic castration-resistant prostate cancer. About 800 participants will receive either the combination or chemot…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New combo therapy aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests whether adding an experimental drug (TVB-2640) to the standard drug enzalutamide is safe for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 30 men will take part, and researchers will monitor side ef…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New drug cocktail aims to stall advanced prostate cancer
Disease control Recruiting nowThis study tests a new two-drug combination (gedatolisib plus darolutamide) in men with metastatic castration-resistant prostate cancer (mCRPC) — a form of prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest and most …
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New 'See and Treat' approach targets tough prostate cancer
Disease control Recruiting nowThis study tests a new approach for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It uses a special molecule that finds cancer cells and delivers both a diagnostic tracer for imaging and a therapeutic dose of radiation. The goal is t…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated May 22, 2026 14:02 UTC